China Medical University Hospital Joins With AbbVie to Promote Innovative Clinical Trial Collaboration

by palligoelme@gmail.com | Mar 13, 2025 | Clinical Trials

​  Li-Yuan Bai, M.D., M.M.S., Ph.D.  Li-Yuan Bai, M.D., M.M.S., Ph.D. 

GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy

by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials

​  /PRNewswire/ — GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for…  /PRNewswire/ — GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced...

Takeda’s Diversity Strategy Pays Off For Phase 3 Trial

by palligoelme@gmail.com | Mar 12, 2025 | Uncategorized

​  LaShell Robinson, head of global feasibility and trial equity at Takeda explains how the company’s Phase 3 trial for a psoriasis drug ended enrollment well before it’s goal and achieved some impressive diversity metrics.  

Research on the Improvement of Intestinal and Immune Functions by Probiotics

by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials

​ Conditions: Intestinal Health Interventions: Dietary Supplement: Probiotic; Dietary Supplement: Placebo Sponsors: Wecare Probiotics Co., Ltd. Not yet recruiting Conditions: Intestinal Health Interventions: Dietary Supplement: Probiotic; Dietary Supplement: Placebo...

Expert Explores Trials in CIS-Refractory Bladder Cancer

by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials

​  Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.  Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder...